Literature DB >> 22455460

Long-term management of scalp psoriasis: perspectives from the International Psoriasis Council.

Knud Kragballe1, Alan Menter, Mark Lebwohl, Paul W Tebbey, Peter C M van de Kerkhof.   

Abstract

The scalp is a well-known predilection site for psoriasis. Epidemiological data on the various manifestations of scalp psoriasis as well as on its therapeutic management are sparse. The understanding of the natural course of scalp psoriasis is relevant for its therapeutic management. In over 25% of patients, scalp psoriasis is the first signal of the psoriatic condition. Nevertheless, few of the therapies currently used for the treatment of scalp psoriasis have been evaluated for efficacy in the setting of well-designed, well-controlled clinical studies. The lack of comparative data impedes the interpretation of the results from studies of scalp psoriasis. Long-term studies of the efficacy and safety of scalp treatments are lacking. Moreover, clinical studies generally do not incorporate quality of life impact or mechanisms to enhance adherence thus hindering the optimal management of the patient over the long-term. Consequently, this report will evaluate the available data and the associated factors to be considered in the development of a treatment paradigm for the long-term management of the scalp psoriasis patient.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22455460     DOI: 10.3109/09546634.2012.681017

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  4 in total

Review 1.  [Psoriasis and eczema on the scalp].

Authors:  D Wilsmann-Theis; T Bieber
Journal:  Hautarzt       Date:  2014-12       Impact factor: 0.751

2.  Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.

Authors:  Arthur Kavanaugh; Philip Helliwell; Christopher T Ritchlin
Journal:  Rheumatol Ther       Date:  2016-02-29

Review 3.  [Psoriasis in special localizations].

Authors:  A Schmieder; W K Peitsch
Journal:  Hautarzt       Date:  2016-06       Impact factor: 0.751

4.  Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab.

Authors:  April W Armstrong; Delfina Guadalupe Villanueva Quintero; Cristina M Echeverría; Yihua Gu; Mahinda Karunaratne; Ofelia Reyes Servín
Journal:  Am J Clin Dermatol       Date:  2016-12       Impact factor: 7.403

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.